Korro Bio (KRRO) EBT Margin (2019 - 2025)
Korro Bio's (KRRO) quarterly EBT Margin came in at 3916.33% in Q4 2025, down 298476.0% on a YoY basis from N/an in Q4 2024, and down 136.35% quarter-over-quarter from 1656.97% in Q3 2025.
Powered by 
Analysis
Korro Bio (KRRO) EBT Margin (2019 - 2025) Analysis & Trends
Korro Bio (KRRO) has reported EBT Margin for 5 consecutive years, with 3916.33% the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, EBT Margin fell 298476.0% year-over-year to 3916.33%; the trailing twelve-month figure through Jun 2026 stood at 4491.94% (down 303803.0% YoY), and the FY2025 full-year result was 1843.18%, up 183362.0% from the prior year.
- EBT Margin declined to 3916.33% in Q4 2025 per KRRO's latest filing, from 1656.97% in the prior quarter.
- Across five years, EBT Margin topped out at 187.38% in Q2 2021 and bottomed at 3916.33% in Q4 2025.
- Historically, EBT Margin has averaged 1401.78% across 3 years, with a median of 931.57% in 2024.
- The sharpest annual moves came in 2021 and 2025: EBT Margin tumbled 11678 bps in 2021, then slumped 298476 bps in 2025.
- Over 3 years, EBT Margin stood at 187.38% in 2021, then tumbled by 397 bps to 931.57% in 2024, then tumbled by 320 bps to 3916.33% in 2025.
- According to Business Quant data, EBT Margin over the past three periods registered 3916.33%, 1656.97%, and 1765.0% for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.78 Bn | 192.79 Bn | 7.24 Bn | 27.53% |
| 2 | Gilead Sciences | 179.92 Bn | 176.74 Bn | 6.22 Bn | -131.41% |
| 3 | Vertex Pharmaceuticals | 131.39 Bn | 123.54 Bn | 2.84 Bn | 41.75% |
| 4 | Regeneron Pharmaceuticals | 81.91 Bn | 73.91 Bn | 3.93 Bn | 35.61% |
| 5 | Argenx Se | 60.35 Bn | 55.17 Bn | 1.37 Bn | 35.78% |
| 6 | Moderna | 53.67 Bn | 48.54 Bn | 52.00 Mn | -528.97% |
| 7 | Alnylam Pharmaceuticals | 33.12 Bn | 29.81 Bn | 992.69 Mn | 13.77% |
| 8 | Biogen | 31.92 Bn | 30.63 Bn | 1.96 Bn | 4.84% |
| 9 | Roivant Sciences | 29.23 Bn | 29.23 Bn | 1.16 Mn | -20,427.46% |
| 10 | Korro Bio | 227.98 Mn | 112.95 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -3,916.33% |
| Sep 30, 2025 | -1,656.97% |
| Jun 30, 2025 | -1,765.00% |
| Mar 31, 2025 | -917.14% |
| Dec 31, 2024 | -931.57% |
| Jun 30, 2021 | -187.38% |
| Mar 31, 2021 | -438.08% |
| Dec 31, 2020 | -103.09% |
| Sep 30, 2020 | -47.35% |
| Jun 30, 2020 | -70.61% |
| Mar 31, 2020 | -67.11% |
| Dec 31, 2019 | -116.65% |
| Sep 30, 2019 | -2.37% |